Engrail Therapeutics Stock

www.engrail.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $221MM

Engrail Therapeutics is a pharmaceutical company that aims to develop treatments for neuropsychiatric and neurodevelopmental disorders that have unmet needs, which include anxiety disorder, depression, and post-traumatic stress disorder. The company strives to use precision-targeted therapies that act on specific parts of the nervous system involved in the disease process with the goal of maximizing effectiveness and minimizing side effects. Engrail Therapeutics was founded in 2019 and is headquartered in San Diego, California.

Register To Buy and Sell Shares

For more details on financing and valuation for Engrail Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Engrail Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Engrail Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Engrail Therapeutics investors also invested in these private companies


Management Team

Vikram Sudarsan Ph.D
Co-Founder, Co-Chief Executive Officer & President
Rex Bosen
Acting Chief Financial Officer
Penelope Przekop
Chief Compliance Officer & Data Protection Officer
Stephen Cunningham MD
Co-Founder & Chief Development Officer
Kimberley Vanover Ph.D
Chief Scientific Officer
Eve Taylor
Vice President of Clinical Development
Anil Vootkur
Vice President of Corporate Development
Quentin McCubbin Ph.D
Chief Technology Officer

Board Members

Jasper Bos Ph.D
Niall O'Donnell Ph.D
RiverVest Venture Partners
Stacie Weninger Ph.D
F-Prime Capital
Tiba Aynechi Ph.D
Norwest Venture Partners

Frequently Asked Questions About Engrail Therapeutics’ Stock

Can you buy Engrail Therapeutics’ stock?
Engrail Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Engrail Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Engrail Therapeutics’ stock?
Yes, you can sell stock of a private company like Engrail Therapeutics. Forge can help you sell your Engrail Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Engrail Therapeutics’ stock price?
Engrail Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Engrail Therapeutics’ private market stock price with Forge Data.
What is Engrail Therapeutics’ stock ticker symbol?
Engrail Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Engrail Therapeutics raises $157 million in funding from F-Prime Capital, others
To continue developing treatment for neurodevelopment disorders, Engrail Therapeutics raised $157 million in a series B round.
Updated on: Apr 21, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.